In a significant move to bolster consumer protections surrounding genetic data, bipartisan senators have introduced a new bill following the bankruptcy of 23andMe, the genetic testing company. Senators John Cornyn and Chuck Grassley, both Republicans, along with Democrat Senator Amy Klobuchar, are advocating for the “Don’t Sell My DNA Act.” This legislation aims to redefine personal data protections in the context of bankruptcy to include sensitive genetic information, addressing increasing privacy concerns among consumers.

Legislative Response to Privacy Concerns

The introduction of the “Don’t Sell My DNA Act” comes as a direct response to privacy issues that have emerged due to 23andMe’s Chapter 11 bankruptcy filing. Senators Cornyn, Grassley, and Klobuchar aim to address increasing consumer apprehension about how sensitive genetic data is handled, especially following the news that 23andMe might sell customer genetic data to a pharmaceutical corporation. By proposing the new legislation, they hope to create a more secure privacy framework for Americans, ensuring that genetic information is treated with the same level of confidentiality as other personal identifiers.

The senators have emphasized the need for updated legal protections, which would fundamentally alter how identity protection is approached in bankruptcy scenarios. With genetics becoming an increasingly vital aspect of personal health knowledge, legislators recognize the urgent need to adapt laws to meet contemporary realities and safeguard individual rights in this evolving landscape.

Understanding the Bankruptcy Code

Currently, the bankruptcy code defines “personally identifiable information” to include data such as an individual’s name, address, social security number, and financial details. However, as technology advances, the nature of personal information has dramatically evolved, necessitating a reevaluation of what constitutes sensitive data. The legislation proposed by Senators Cornyn, Grassley, and Klobuchar seeks to amend this definition to include genetic data, which is currently not protected under existing law. This gap leaves individuals vulnerable to privacy breaches, especially in instances where a company files for bankruptcy and its assets, including sensitive information, are at risk of being mismanaged or misappropriated.

The lawmakers argue that by including genetic data within the confines of the definition of “personally identifiable information,” consumers would receive the enhanced protection they require. This change would not only deter potential misuse during bankruptcy proceedings but would also encourage greater consumer confidence in genetic testing companies, pushing them to take more rigorous steps in data safeguarding.

The Role of Genetic Information in Consumer Data

The significance of genetic information cannot be understated; it not only reveals profound insights into an individual’s health but can also have implications for family members. As more people engage with genetics through services offered by companies like 23andMe, the need for stringent data regulations becomes increasingly essential. The senators highlighted the pressing concern that existing laws have not kept pace with technological advancements, thereby failing to protect consumer data adequately.

The proposed bill would compel companies to secure explicit consent from customers before any potential sale or lease of their genetic information in bankruptcy scenarios. It would also require companies to provide prior written notice concerning the use or sale of genetic information. The role that such legislative measures play is pivotal in ensuring that individuals maintain control over their genetic information, particularly during tumultuous events such as corporate bankruptcies where a wealth of sensitive data might change hands without adequate oversight.

Current Financial Status of 23andMe

23andMe filed for Chapter 11 bankruptcy earlier this year, attributed to a mix of financial struggles and management restructuring. The company is now under the process of auctioning off its assets, with pharmaceutical giant Regeneron agreeing to purchase 23andMe for $256 million. This acquisition is designed to consolidate substantial parts of the company, including its personal genome service and health research segments. The unfolding dynamics surrounding 23andMe serve to spotlight the specific vulnerabilities inherent in a data marketplace increasingly reliant on consumer trust.

Given the sale of the company, there remains a broader conversation about how consumer genetic data is being managed by merging corporate interests and consumer privacy. With Regeneron’s commitment to a secure transfer of consumer information, the transaction underscores the necessity for legislative action to preempt potential data privacy concerns that may arise in similar scenarios in the future.

Implications of the Bill for the Future

If successfully passed, the “Don’t Sell My DNA Act” could serve as a significant turning point in the way genetic information is protected under U.S. law. It would facilitate a framework of accountability for companies operating within the genetic testing landscape, ensuring that consumers are not left vulnerable when private companies face bankruptcy. The protections laid out in the bill suggest a recognition by lawmakers that genetic data poses unique challenges and risks that differ from other traditional types of personal information.

Providing consumers with the power to assert control over how their genetic information is used and limiting its potential for exploitation marks a new frontier in the conversation about privacy rights. The future implications of this bill extend beyond just changes in bankruptcy law; they also represent a broader movement towards enhancing consumer rights in digital arenas, potentially fostering more robust regulations in privacy across various sectors.

Summary

The proposed “Don’t Sell My DNA Act” represents a proactive legislative approach to adapt to modern challenges surrounding consumer data privacy, particularly as it pertains to genetic information. By redefining personal data protections in the context of bankruptcy, the bill aims to close critical gaps in existing consumer safeguards, thereby enhancing public confidence in genetic testing services. With the recent bankruptcy of 23andMe serving as a catalyst for these changes, this legislative effort signals a necessary step toward ensuring that sensitive genetic information is treated with the utmost care and respect in a rapidly changing technological landscape.

Frequently Asked Questions

Question: Why is there a need for the “Don’t Sell My DNA Act”?

The bill addresses gaps in current consumer protections regarding genetic information, especially in situations where companies file for bankruptcy, ensuring that sensitive data is secure and not misused.

Question: What is the current status of 23andMe?

23andMe has filed for Chapter 11 bankruptcy and is in the process of selling its assets to Regeneron Pharmaceuticals, among other financial adjustments due to ongoing challenges.

Question: How would the proposed legislation change consumer rights over genetic data?

The legislation would require explicit consumer consent for the sale or lease of genetic data during bankruptcy and would enhance overall privacy protections for individuals’ genetic information.

©2025 News Journos. All rights reserved.

The genetic testing company 23andMe has filed for Chapter 11 bankruptcy, igniting discussions about the implications this may have on consumer data security and law enforcement access to genetic information. With over 15 million users, the company’s potential sale could mean a significant increase in the database available to authorities for solving cold cases. Experts weigh in on the risks associated with the potential access to user data, including past breaches and the ethical responsibility of handling sensitive personal information.

Implications of 23andMe’s Bankruptcy

On [date of filing], 23andMe officially filed for Chapter 11 bankruptcy amid ongoing financial challenges. The co-founder, Anne Wojcicki, has expressed intentions to buy back the company after stepping down as CEO, but the board has reportedly rejected her recent offer. This bankruptcy not only raises questions about the company’s future but also reveals the precarious state of data handling in the genetics industry. The filing has affected over 15 million customers who are now unsure about the future of their personal information and genetic data.

As a major provider of genetic testing services, 23andMe enabled individuals to provide saliva samples for analysis, linking consumers to ancestry and possible health predispositions. However, this convenience poses a significant ethical dilemma, particularly as their operational model has increasingly come under scrutiny. As the financial situation unfolds, the potential sale of 23andMe could have serious implications for the handling of consumer genetic data.

Law Enforcement and Genetic Data

The intersection of genetic testing and law enforcement has become a focal point of debate following 23andMe’s bankruptcy announcement. Historically, 23andMe has maintained a reluctant stance toward sharing its customer data with law enforcement, typically complying only with legitimate subpoenas or court orders. In their most recent Transparency Report, they disclosed receiving 15 requests from law enforcement but did not fulfill any.

Experts suggest that the acquisition of 23andMe’s database could drastically enhance law enforcement’s investigative capabilities, potentially leading to breakthroughs in cold cases. Eric Brown, CEO of Imperio Consulting, noted that a substantial increase in genetic profiles could empower police departments in ways not previously possible. The likelihood that merely a fraction of evidence could lead to significant progress in solving crimes is not ruled out. “The least sliver of DNA from a criminal could 100% help law enforcement,” he stated, emphasizing the utility of genetic information in modern forensic practices.

Previous Cases Highlighting DNA’s Impact

The power of DNA databases in solving unresolved criminal cases gained widespread recognition following the arrest of the infamous Golden State Killer in 2018. The suspect, Joseph DeAngelo, was caught utilizing genetic genealogy—a method involving DNA analysis and family tracing. His case exemplifies how investigators can leverage consumer DNA databases to make significant strides in long-dormant investigations. As a result of this investigative approach, DeAngelo was sentenced for multiple murders and rapes that plagued California decades earlier.

Similarly, the complex case of Casey Anthony, charged in 2008 with the murder of her 2-year-old daughter, utilized DNA evidence to identify remains. Although ultimately acquitted of the murder charges, DNA’s pivotal role in the Anthony case illustrated technical and ethical challenges that continue to present in the intersection of crime and genetic data. As such cases continue to unfold, the outcome has implications for how genetic testing companies handle sensitive information moving forward.

Consumer Concerns Over Data Security

The bankruptcy filing has led consumers to express significant apprehensions regarding data security. As Darren Williams, founder of BlackFog Inc., noted, the possibility of sensitive genetic information falling into the wrong hands presents immediate risks. The recent cyber breach affecting 0.1% of 23andMe’s users in 2023 highlighted the vulnerabilities inherent in sharing genetic data with third-party organizations. Hackers were able to access user accounts and exploit the platform’s DNA Relatives feature to gain access to additional user information.

In light of these developments, many customers have been prompted to question the value of participating in genetic testing services that may compromise their personal health information. Concerns about how accurately genetic data is protected are on the rise, drawing attention to the potential lifetime consequences of a data breach. As the door opens for new buyers in the market, the need for stronger safeguards can no longer be ignored.

The Future of Genetic Testing Firms

The trajectory of genetic testing companies is uncertain as the industry grapples with declining consumer interest and increasing wariness about data privacy. Eran Barak, CEO of MIND, noted that the growth in popular interest that propelled 23andMe and similar firms to their heights appears to have plateaued. As concerns mount about how data is handled, firms may be compelled to rethink their business models.

Observers predict a potential shift towards monetizing DNA data through partnerships with research and pharmaceutical institutions in a bid to remain viable. However, with the resultant loss of consumer trust, this strategy could fantastically backfire, risking further consumer disengagement while creating a new realm of ethical and legal dilemmas to navigate. As 23andMe’s case illustrates, the challenges faced by such firms are multi-faceted and layered.

Summary

The bankruptcy of 23andMe signals a crucial point in the future of genetic testing companies and the handling of consumer data. As discussions surrounding law enforcement access to genetic information and the privacy rights of individuals gain momentum, stakeholders in the industry must remain vigilant. Consumers increasingly demand transparency and security, driving the need for firms to create ethical standards that protect sensitive health information. Moving forward, how these companies adapt will determine not only their survival but also the trust they earn from their customer base.

Frequently Asked Questions

Question: How does the bankruptcy of 23andMe affect my genetic data?

The bankruptcy filing raises concerns about potential risks to customer data security. Consumers are advised to stay updated regarding any developments concerning 23andMe and consider the implications for their personally identifiable information.

Question: What options do consumers have for protecting their genetic data?

Consumers should remain informed about privacy policies and consider alternative genetic testing companies that demonstrate stronger commitments to data security. Taking proactive steps such as opting out of features that share data can also help.

Question: What role has DNA played in recent criminal investigations?

DNA evidence has increasingly played a pivotal role in solving cold cases, as seen in high-profile cases like the Golden State Killer and Casey Anthony. Law enforcement agencies have effectively utilized genetic genealogy to identify suspects in previously unresolved investigations.

©2025 News Journos. All rights reserved.

The genetic testing company 23andMe has filed for Chapter 11 bankruptcy, a notable decline for a firm once valued at $6 billion in 2021. The filing comes in light of ongoing financial challenges, a significant leadership overhaul, and increasing concerns regarding the protection of customer genetic data. As the company embarks on a court-supervised sale process, many customers are left wondering what this means for their sensitive information and what steps they can take to safeguard it in this new context.

The fall of 23andMe: A timeline of challenges

23andMe’s trajectory has been marked by a series of serious setbacks leading to its current bankruptcy situation. Once valued at $6 billion in 2021, the company has faced a series of challenges that have contributed to its decline. In 2023, a significant data breach compromised the genetic and personal information of approximately 7 million users. This cyberattack not only led to legal actions against the firm but also triggered reputational harm that has proven difficult to recover from.

Moreover, the company experienced a notable leadership change when CEO Anne Wojcicki resigned during the bankruptcy announcement, hinting at her potential interest in purchasing the company herself. The financial troubles are further underscored by the plummeting stock price, which fell from over $300 per share to less than $1, revealing the dire state of the organization’s fiscal health. Initiatives to cut costs followed, culminating in a 40% workforce reduction announced in November 2024.

By March 23, 2025, 23andMe pursued voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri. This legal move was aimed at facilitating a sale process designed to optimize the value of the business. Despite the alarming nature of these developments, the company has reassured users that there will be no immediate changes regarding how customer data is stored or managed, although concerns continue to loom about the potential sale of genetic information.

23andMe board seeks to maximize value through a court-supervised sale

In statements surrounding the bankruptcy filing, Mark Jensen, the chair and member of the special committee of the board of directors of 23andMe, emphasized that a thorough evaluation prompted the decision to engage in a court-supervised sale process. “We expect the court-supervised process will advance our efforts to address the operational and financial challenges we face, including further cost reductions and the resolution of legal and leasehold liabilities,” Jensen explained.

He further acknowledged the dedication of the workforce and reassured them of the company’s commitment to safeguarding customer data, insisting that user data management will remain transparent throughout this transition. “Data privacy will be an important consideration in any potential transaction,” he added, conveying a cautious optimism about the future of 23andMe’s mission of facilitating access to genetic information for customers and patients.

What happens to your genetic data during bankruptcy?

The bankruptcy process can complicate the handling of sensitive customer data, as the assets of a company, including genetic data, can be incorporated into the sale. Various state privacy laws, like California’s Genetic Information Privacy Act, demand explicit consumer consent before transferring genetic data to another party. However, despite these legal protections, there exists a risk of misuse or inadequate protection during the transition period.

In a reassuring statement, 23andMe has asserted that any new owner will be mandated to comply with existing privacy laws, but the intrinsic value of genetic data poses ongoing risks if not diligently safeguarded. Compounding this situation, shortly before the bankruptcy filing, 23andMe updated its terms of service, introducing new legal stipulations that could inhibit individuals’ ability to pursue lawsuits, effectively funneling claims into binding arbitration unless a user opts out within 30 days.

Customers are urged to proactively protect their rights by opting out of these terms by emailing arbitrationoptout@23andme.com with a notification from the email account linked to their profiles. This measure is crucial for those concerned about preserving their legal options moving forward.

Steps to protect your genetic data

For individuals who are users of 23andMe or are contemplating using similar genetic testing services, maintaining the security of sensitive genetic information is paramount. Here are several recommended steps:

1) Opt out of arbitration: Users should notify 23andMe of their intention to opt out of any arbitration agreements within 30 days of first use by sending an email to arbitrationoptout@23andme.com.

2) Review privacy preferences: Regularly assessing privacy and data-sharing settings can help users ensure these settings are in line with their comfort levels concerning data use.

3) Limit research participation: Individuals should consider disabling participation in research or product development initiatives if there are concerns about how their data might be utilized.

4) Download and secure your data: Before account deletion, downloading genetic records for safe storage on encrypted devices or cloud services is advisable.

5) Request data deletion: Users can seek the deletion of their data by accessing account settings and requesting the destruction of any physical samples alongside digital data.

6) Use strong passwords and multifactor authentication: Creation of robust, unique passwords for each account is vital, in addition to enabling two-factor authentication wherever available to prevent unauthorized access even if passwords are compromised.

7) Monitor for suspicious activity and use identity theft protection: Signing up for identity theft protection services can help users stay informed about their personal info. These services often offer crucial support in the event of identity theft and may include insurance to cover potential losses.

Kurt’s key takeaways

The recent bankruptcy of 23andMe stands as a cautionary tale reflecting the risks associated with sharing sensitive genetic information. Despite the company’s commitment to uphold privacy standards during this unsettling time, consumers must remain proactive to shield themselves against potential privacy risks. The ownership transfer of valuable genetic data highlights the importance of taking control of one’s own data, whether through adjusting privacy settings, requesting account deletions, or opting out of imposed legal terms.

Summary

The bankruptcy of 23andMe underscores the essential considerations consumers must reflect upon regarding the use of genetic testing services. With heightened scrutiny over data protection amid corporate turmoil, users of such platforms should remain vigilant and informed about their rights. By proactively managing their genetic data and understanding the implications of the company’s financial actions, consumers can better navigate potential risks associated with the ongoing situation at 23andMe.

Frequently Asked Questions

Question: What are the implications of 23andMe’s bankruptcy for customer data?

23andMe’s bankruptcy may affect the handling of customer data as it can be included in the sale of company assets. There are laws that protect genetic data, but risks remain regarding its transfer and potential misuse.

Question: How can I protect my genetic data during this time?

Customers can protect their data by opting out of arbitration agreements, reviewing privacy preferences, limiting research participation, and requesting data deletion if preferred.

Question: What legal protections are in place for genetic data?

Many states have laws requiring explicit consent before transferring genetic data to new owners. However, customers should remain proactive in safeguarding their rights.

©2025 News Journos. All rights reserved.

©2025 News Journos. All rights reserved.

©2025 News Journos. All rights reserved.